INTRODUCTION
Thyroid cancer rates have nearly tripled in the last 3 decades. 1 This rise may reflect increased incidental reporting due to more reliable and widespread screening. Well-differentiated papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) account for most cases, with PTC carrying an excellent prognosis. That of FTC hinges on the extent of invasion, but is worse than PTC even when confined to the thyroid. 2 Undifferentiated anaplastic thyroid cancer (ATC) is the deadliest, with a 5-year disease-free survival rate of nearly 0%. Although PTC, FTC, and ATC are histologically distinct, they are interconnected across a continuum of differentiated states. This is clinically relevant because malignant variants may arise from dedifferentiation of well-differentiated disease. 3 Consequently, aggressive PTC and FTC phenotypes resulting in extrathyroidal extension and metastases are often treatment-refractory and more likely to recur. This underscores the need to identify therapeutic targets that drive thyroid cancer differentiation.
The Notch family (Notch1-4) is fundamental to normal development and the cancer phenotype. 4 In murine keratinocytes, Notch signaling has been found to induce cell-cycle arrest and terminal differentiation, whereas its absence preserves progenitor cell characteristics during early differentiation. 5 Notch's conserved function is exemplified during lateral inhibition wherein its underexpression promotes self-renewal of stem cells, while its activation prompts entry into transitamplifying populations, fate specification, and mitotic arrest. 6, 7 Accordingly, the Notch1 isoform is downregulated in lesser differentiated cancers, including small cell lung cancer, medullary thyroid cancer (MTC), basal cell carcinomas, and neuroendocrine cancers. [8] [9] [10] [11] Moreover, Notch1 activation in these cancers reduces proliferation and biomarkers of malignancy. Notch1 also behaves as a tumor suppressor in human papillomavirus-driven cervical cancer, myeloid leukemia, and epithelial thyroid cancers, including PTC, FTC, and ATC. [12] [13] [14] [15] Although Notch1's role in thyroid cancer has been well reported, the Notch3 isoform remains underexplored. Along with its distinct structure and specificity to proliferating neuroepithelium, Notch3 promotes cellular senescence in human fibroblasts by transactivating p21
Waf1/Kip1 , similar to Notch1. 5, 11, 16, 17 Notably, in MTC, Notch3 is expressed at near absent levels, while its activation induces apoptosis. 18 Given the antiproliferative effect of Notch signaling during normal differentiation and in certain cancers, we were interested in Notch3's role across the developmental spectrum of epithelial thyroid cancers. We demonstrate that Notch3 is expressed in normal and benign thyroid, but is progressively diminished across decreasingly differentiated thyroid cancer subtypes. Moreover, Notch3 activation reduces FTC cell proliferation and tumor burden in vivo.
MATERIALS AND METHODS

Tissue Microarray (TMA) and Human Thyroid Cancer Samples
Our TMA contained formalin-fixed, paraffin-embedded thyroid biopsies from 155 patients at the University of Wisconsin Hospitals and Clinics. These included 10 normal thyroids from contralateral lobes of PTC patients, 10 nodular goiters, 11 cases of Hashimoto's thyroiditis, 32 follicular adenomas, 28 PTCs, 28 FTCs, 27 follicular variants of papillary thyroid cancer (FVPTCs), and 9 ATCs, each mounted in triplicate for a total of 465 cores (excluding detached cores). We also acquired 5 PTCs, 4 FTCs, 2 ATCs, 1 colorectal cancer, and 1 pancreatic adenocarcinoma from the Comprehensive Cancer Center Biobank (University of Wisconsin -Madison), from which lysates were prepared for Western blotting as previously described. 18 Protocols were Institutional Review Boardapproved.
TMA Staining and Image Acquisition
Notch3 expression was quantified within each core's nucleus and cytoplasm with the Vectra 3.0 workflow as previously described, using an anti-Notch3 polyclonal antibody (Santa Cruz, Houston, Tex). 19 Total Notch3 staining was used to stratify patients into low-and highexpression groups using the median of 0.15 as the cutoff. Spectral libraries were assembled using Nuance 3.0.0 and inForm 1.2 (Caliper Life Sciences, Hopkinton, Mass; see Supplementary Methods in the online supporting information).
Tissue Culture
Nontumorigenic, human epithelial thyroid cell lines Nthy-ori 3-1 and HTori-3, and human FTC cell lines FTC133 and FTC236 were purchased from Sigma Life Science/European Collection of Cell Cultures. BCPAP, TPC1 (both human PTC lines) and 8505C (human ATC line) were gifts from Dr. Daniel Ruan (Brigham and Women's Hospital, Boston, Mass), and HTh7 (human ATC cell line) was a gift from Dr. Rebecca Schweppe (University of Colorado, Denver, Colo). Cell lines were used within 6 months of their receipt or recovery from cryopreserved stocks, and underwent short tandem repeat profiling and mycoplasma screening to verify their authenticity (see Supplementary Methods in the online supporting information).
NOTCH3 Gene Silencing
Transient NOTCH3 knockdown was performed in FTC133 cells using 150 nM of either a gene-specific small interfering RNA (siRNA) against NOTCH3(h) (catalog no. sc-37135; Santa Cruz Biotechnology, Dallas, Tex), or a nonspecific siRNA (catalog no. sc-37007; Santa Cruz Biotechnology) as a negative control. Transfections were performed using Lipofectamine 2000 (Life Technologies, Grand Island, NY) per manufacturer's instructions.
Doxycycline-Inducible NOTCH3 Expression in FTC236 Cells
Our inducible line (FTC236-NOTCH3 intracellular domain [NICD3]) and control line (FTC236-tetracyclineresponse element [TRE]) were constructed with the pRevTet-On/TRE system (Clontech, Takara Bio, Mountain View, Calif) using a plasmid containing the NICD3 fragment, or an empty vector, respectively (see Supplementary Methods in the online supporting information).
Western Blotting
Total cell lysates were prepared for Western blotting as previously described (for antibodies, see Supplementary Table 1 in the online supporting information) using SuperSignal West Pico, Femto, Dura (Pierce, Rockford, Ill), or Immun-Star chemiluminescence kits (Bio-Rad Laboratories, Hercules, Calif) to detect antibody binding. 18 Densitometric quantification was performed using ImageJ (National Institutes of Health, Bethesda, Md).
Quantitative Real-Time Polymerase Chain Reaction
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to quantify NOTCH3, hairy/enhancer-ofsplit 1 (HES-1), hairy/enhancer-of-split related with YRPW motifs 1 and 2 (HEY-1 and HEY-2), sodiumiodide symporter (NIS; also known as solute carrier family 5 member 5 [SLC5A5]), thyroid-stimulating hormone receptor (TSHR), and thyroid transcription factors 1 and 2 (TTF-1 and TTF-2) message. Primer sequences are listed in Supplementary Table 2 (see this table and Supplementary Methods in the online supporting information).
Luciferase Reporter Assay
A luciferase construct containing 4 centromere-binding protein 1 (CBF1)-binding sites (43CBF1-Luc) was transiently transfected into FTC236-NICD3 and FTC236-TRE cells, followed by 48 hours of doxycycline treatment (0-1.0 mg/mL). Reporter activity was measured using the ONE-Glo Luciferase Assay System (Promega Corp., Madison, Wis). A cytomegalovirus b-galactosidase gene cotransfection served as a control for transfection efficiency.
Cell Viability Assay
Thyroid cancer cell viability was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide rapid colorimetric assay as previously described.
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FTC236-TRE and FTC236-NICD3 cell proliferation was assessed following 2 and 4 days of doxycycline treatment (0-1.0 mg/mL).
In Vitro Scratch Assay and CytoSelect Cell Migration and Invasion Assay FTC133, FTC236-NICD3, and FTC236-TRE cell migration following NOTCH3 siRNA, nonspecific siRNA, or doxycycline treatment (0-1.0 mg/mL) was assessed using an in vitro scratch assay, or the CytoSelect Cell Migration and Invasion Assay (Cell Biolabs, Inc, San Diego, Calif; see Supplementary Methods in the online supporting information).
Detection of Apoptosis by Phycoerythrin (PE) Annexin V/7-Aminoactinomycin D (7-AAD) Staining FTC236-NICD3 and FTC236-TRE cells treated with doxycycline (0-1.0 mg/mL) for 48 hours were harvested and stained with PE Annexin V and 7-AAD fluorescein solutions (BD Pharmingen, San Jose, Calif) per manufacturer's instructions. Flow cytometry and quantitative fluorescent sorting were performed as described previously using the FACSCalibur fluorescence-activated cell sorting instrument (BD Biosciences, San Jose, Calif), and analyzed using FlowJo (version 10.0.8; TreeStar, Inc, Ashland, Ore). 14 
Animal Studies
Four-week-old athymic mice were acclimated for 1 week in a pathogen-free facility. A 10 7 cell suspension of FTC236-NICD3 or FTC236-TRE cells in Hanks' Balanced Salt solution (Cellgro, Manassas, Va) was injected subcutaneously into the right rear flank of each mouse. Mice carrying FTC236-NICD3 xenografts were fed pre-irradiated chow containing low-dose doxycycline (200 mg/kg), high-dose doxycycline (625 mg/kg), or no doxycycline (HarlanTeklad, Madison, Wis). Mice carrying FTC236-TRE xenografts were fed doxycycline-free or high-dose doxycycline chow. Doxycycline-containing diets commenced 1 week prior to tumor injection. Tumor dimensions were measured by external caliper every 3 days, and their volumes were then calculated based on the modified ellipsoidal formula:
Forty-five days following tumor visualization (59 days of treatment), mice were sacrificed, and their tumors were resected, flash-frozen in liquid nitrogen, and processed into lysates for Western analysis as previously described. 18 Animal handling was overseen by the Animal Care and Use Committee of the University of WisconsinMadison.
Statistical Analyses
Data are presented as a mean value 6 standard error of the mean. Means were compared using Student's t-testing (SPSS version 22; IBM, Armonk, NY), or log-corrected, 2-way Analysis of Variance with Tukey's adjustment for multiple comparisons. Fisher's least significant difference testing was also performed for post hoc comparisons (version 9.3; SAS, Cary, NC). Area under the receiver operating characteristic (AUROC) curve analysis was used to assess whether Notch3 expression among TMA specimens predicted malignancy. Survival was plotted using KaplanMeier and Cox proportional hazards (PH) modeling (SPSS version 22; IBM). Unadjusted survival was determined based on univariate Cox PH testing of Notch3 as a single variable. To then control for clinicopathological features affecting survival, adjusted survival was determined using a multivariate Cox PH approach, incorporating Notch3 with other clinically relevant covariates to evaluate it as an independent prognosticator. Among these covariates, TNM stage, tumor size, extrathyroidal extension, and distant metastasis were designated as categorical in SPSS based on specified cutoff values (Tables 2  and 3 ). Covariates were fixed to the lesser aggressive phenotypic category for each (TNM stage I, II, or III; tumor size 50 mm; no extrathyroidal extension; no distant metastasis) when generating Cox regression curves representing both adjusted models ( Figure 1C ). Age was the only covariate treated as continuous, and to which adjusted survival curves were fixed at its mean. This covariate profile was chosen because the majority of our study's patients exhibited these more benign attributes. All PH assumptions were tested and not violated. P values less than .05 were considered statistically significant.
RESULTS
Notch3 Expression Correlates With Thyroid Cancer Pathology
To determine Notch3's clinical relevance, we compared mean intranuclear, intracytoplasmic, and combined Notch3 expression between diagnostic groups on our TMA (Fig. 1A) . Normal thyroid tissue exhibited the ROC curve analysis was used to discriminate malignant thyroid pathologies (PTC, follicular variant of PTC, FTC, and ATC) from benign pathologies (nodular goiter, Hashimoto's thyroiditis, and follicular adenoma) on the basis of Notch3 expression. This generated an area under the ROC curve of 68.8%. (C) The KaplanMeier plot compared overall survival of patients with tumors expressing low Notch3 levels (intensity 0.15) to patients with tumors expressing high Notch3 levels (intensity > 0.15) via log-rank testing. The latest patient follow-up was 24.4 years. Unadjusted survival between the low and high Notch3 groups was also compared using univariate Cox PH modeling. Adjusted survival with respect to Notch3 expression was assessed using a multivariate Cox PH approach. 1 Survival adjusted for patient age at diagnosis, TNM stage, tumor size, extrathyroidal extension, and distant metastasis. 2 Survival adjusted for patient age at diagnosis, tumor size, and extrathyroidal extension. ATC, anaplastic thyroid cancer; FTC, follicular thyroid cancer; PH, proportional hazards; PTC, papillary thyroid cancer; ROC, receiver operating characteristic.
highest mean Notch3 immunostaining intranuclearly (0.199) and intracytoplasmically (0.104). Notch3 regressed across decreasingly differentiated thyroid pathologies (see Supplementary Table 3 in the online supporting information). TNM stage, tumor size, extrathyroidal extension, distant metastasis, and vessel invasion correlated inversely with mean cytoplasmic and/or nuclear Notch3 (Table 1) .
Similar trends occurred among thyroid cancer cell lines and specimens. Nontumorigenic cell lines (Nthyori-1-3 and HTori-3) displayed the highest relative NOTCH3 message, followed by PTC (BCPAP and TPC1), FTC236, and ATC (8505c and HTh7) cell lines ( Fig. 2A) . FTC133, derived from a primary FTC tumor, possessed the highest NOTCH3 message off all thyroid cancer cell lines, including FTC236, established from a lymph node metastasis of the same tumor. NICD3 protein expression was lower in all cancer lines relative to both nontumorigenic thyroid lines (Fig. 2B) . NICD3 represents the active portion of full-length Notch3 that, once cleaved, executes downstream signaling intranuclearly. Among human samples tested, NICD3 was less expressed in FTCs and ATCs compared to PTCs. Colorectal cancer and pancreatic adenocarcinoma samples served as positive controls (Fig. 2C) . 20, 21 To further elucidate Notch3's relation to thyroid cancer aggression, NOTCH3 was suppressed in FTC133 using a gene-specific siRNA (Fig. 2D) . FTC133 was selected because it exhibited high baseline Notch3 expression and was FTC236's nonmetastatic counterpart. We have previously reported that FTC133 has a slower migratory rate than that of FTC236, consistent with its relatively benign phenotype. 22 NOTCH3 suppression significantly enhanced cell migration (P 5 7.8 3 10
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; Fig. 2E ) and inhibited transcription of thyrocyte differentiation markers TTF-1 (P 5 .01), TTF-2 (P 5 .07), and TSHR (P 5 .05; Fig. 2F ).
Notch3 Levels in Thyroid Cancer Are Associated With Prognostic Variables and Long-Term Survival
Receiver operating characteristic (ROC) analysis was performed to determine whether Notch3 expression could discriminate benign from malignant thyroid pathologies. The benign group comprised nodular goiters, Hashimoto's thyroiditis, and follicular adenomas, while the malignant group included PTC, FVPTC, FTC, and ATC. Because the 10 normal thyroid samples came from PTC patients also represented on the TMA, these were excluded from ROC analysis to preserve sample independence. Notch3 levels distinguished benign from malignant diagnoses (AUROC, 68.8%; Fig. 1B ).
Kaplan-Meier analysis revealed that thyroid cancers expressing lower Notch3 levels (intensity 0.15) correlated with decreased overall survival compared to the higher Notch3 group (intensity > 0.15; log-rank test P 5 .007; Figure 2 . Notch3 levels correlate with thyroid cancer differentiation status. (A) Relative NOTCH3 message levels were measured using qRT-PCR in normal thyroid cell lines (Nthy-ori-3-1 and HTori-3), PTC lines (BCPAP and TPC1), FTC lines (FTC133 and FTC236), and ATC lines (8505c and HTh7). Cycle numbers were acquired at the log-linear phase of each reaction. The comparative DC t method was used to measure gene transcription relative to levels of either S27 or glyceraldehyde 3-phosphate dehydrogenase controls. Data are expressed as the mean6SEM of triplicates from 1 experiment, and are representative of 2 independent experimental repeats (*P <.001 relative to Nthy-ori-3-1 and HTori-3). Primer sequences are listed in Supplementary Table 2 (see online supporting information). (B) The expression of NICD3 in these cell lines was also determined by Western blotting. (C) Human tissue samples, including 5 PTC tumors, 4 FTC tumors, and 2 ATC tumors, were assessed for their levels of NICD3 by Western blotting, as well. CRC and PA served as positive controls. b-Actin was used as a loading control. (D) NOTCH3 transcription was measured using qRT-PCR following transfection of FTC133 cells with NOTCH3 siRNA, or NS siRNA, and calculated relative to S27 control levels using the comparative DC t approach. Relative NOTCH3 message from NOTCH3 siRNA-treated cells was then normalized to that from NS siRNA-treated cells to convey NOTCH3 fold suppression. (E) A 2-dimensional scratch assay was used to determine the effect of NOTCH3 suppression on FTC cell migration. Confluent plates of FTC133 treated with NOTCH3 siRNA or NS siRNA were scratched vertically to create a cell-free zone, and light microscopy photographs (310) were then taken 0 and 48 hours following transfection. At 48 hours, gap closure was measured in micrometers using MRGrab. The remaining cell-free space relative to the original width of the scratch is represented in the adjacent graph as the gap closure fraction, signifying the degree of cell migration. (F) Following NOTCH3 silencing in FTC133, qRT-PCR was used to measure the transcription of thyroid-specific differentiation markers including TTF-1, TTF-2, and TSHR. Transcription of each marker was calculated relative to S27 control levels using the comparative DC t method. Fold transcriptional changes were then determined by normalizing relative message levels from NOTCH3 siRNA-treated cells to those from NS siRNA-treated cells. All data are represented as the mean6SEM of triplicates from 1 experiment, and reflect the findings of 2 independent experimental repeats. DC t , cycle threshold; ATC, anaplastic thyroid cancer; CRC, colorectal cancer; FTC, follicular thyroid cancer; NICD3, Notch3 intracellular domain; NS, nonspecific; PA, pancreatic adenocarcinoma; PTC, papillary thyroid cancer; qRT-PCR, quantitative real-time polymerase chain reaction; siRNA, small interfering RNA; TSHR, thyroid-stimulating hormone receptor; TTF, thyroid transcription factor; SEM, standard error of the mean. Fig. 1C ). Notably, all ATC patients were classified in the low Notch3 group and died after surgery. To eliminate these outliers, well-differentiated thyroid cancers (PTC, FVPTC, and FTC) were assessed alone, after which Notch3's association with survival was no longer significant (log-rank test P 5 .183; data not shown).
Univariate Cox PH analysis linked poorer patient survival to each of several clinicopathological variables, including age, TNM stage, tumor size, extrathyroidal extension, and distant metastasis (Table 2 ), in addition to low Notch3 expression (Fig. 1C [Cox Regression-Unadjusted Overall Survival]; P 5 .014; hazard ratio, 4.772). Using multivariate Cox PH analysis to adjust for these variables, low Notch3 expression correlated more strongly with poor patient survival (P 5 .028; hazard ratio, 6.574), demonstrating it to be an independent predictor of survival (Fig. 1C [Cox Regression-Adjusted Overall Survival] and Table 2 ). On univariate analysis of only welldifferentiated thyroid cancer patients (PTC, FVPTC, and FTC), low Notch3 expression generated a hazard ratio of 2.465, but did not significantly predict survival (Fig. 1C [Cox Regression-Unadjusted Overall Survival, Welldifferentiated Only] and Table 3 ). Following multivariate analysis adjusting for age, tumor size, and extrathyroidal extension, Notch3's prognostic value approached significance (P 5 .088), increasing the hazard ratio to 4.12 ( Fig.  1C [Cox Regression-Adjusted Overall Survival, Welldifferentiated Only] and Table 3 ).
Notch3 Induction Activates Functional Downstream Signaling
In FTC236-NICD3, doxycycline treatment (0-1.0 mg/ mL) for 48 hours dose-dependently increased NICD3 expression, whereas the empty vector line FTC236-TRE exhibited no induction (Fig. 3A) . To verify functional NICD3 activity, qRT-PCR was performed on HES and HEY, known downstream Notch signaling targets. 23 Doxycycline treatment of FTC236-NICD3 significantly activated HES-1, HEY-1, and HEY-2 transcription (P < .0001; Fig. 3B-D) , and increased relative CBF1-luciferase activity (P 5 .01; Fig. 3E ). Canonical Notch signaling causes NICD to complex with CBF1 intranuclearly, which displaces transcriptional repressors located on Notch target genes HES and HEY. 24 These results demonstrate functional Notch3 activation in our gain-offunction model. 
Notch3 Induction Inhibits Cell Proliferation and Migration
Doxycycline treatment reduced FTC236-NICD3 proliferation following doses of 0.2 mg/mL (P < .003) and higher (P < .0001), but did not affect FTC236-TRE proliferation (Fig. 4A ). NICD3 induction also inhibited HTh7 proliferation (see Supplementary Fig.  1 in the online supporting information). Additionally, doxycycline treatment of FTC236-NICD3 suppressed migratory gap closure (P < .0001) and cell migration, as demonstrated using the CytoSelect Cell Migration and Invasion Assay (P 5 .04; Fig. 4B ). were then taken following 0 and 48 hours of treatment. Gap closure following 48 hours was measured in micrometers using MRGrab. The gap closure fraction represents the remaining cell-free space relative to the original width of the scratch, and reflects the degree of cell migration. The CytoSelect Cell Migration and Invasion Assay was also used to determine the effect of Notch3 activation on cell migration. FTC236-NICD3 or FTC236-TRE cells (1 3 10 5 cells) were cultured inside each CytoSelect transwell, with or without DOX treatment (1.0 mg/mL). Following 12 hours, cells that had transmigrated across the discriminatory membrane were quantified by OD (560 nm) according to manufacturer's instructions. (C) qRT-PCR was used to measure the normalized fold transcription of various markers of thyrocyte differentiation. FTC236-NICD3 and FTC236-TRE cells treated with DOX (1.0 mg/mL) for 48 hours were then assessed for message levels of NIS, TSHR, TTF-1, and TTF-2. The comparative DC t method was used to calculate the mean fold activation of each differentiation marker relative to either S27 or glyceraldehyde 3-phosphate dehydrogenase control levels, following DOX treatment. Transcriptional activation was then determined by normalizing relative transcription levels from treated cells to those from untreated cells. All data are expressed as the mean6SEM of triplicates from 1 experiment, and reflect the findings of 2 independent experimental repeats. DC t , cycle threshold; DOX, doxycycline; FTC, follicular thyroid cancer; NICD3, Notch3 intracellular domain; NIS, sodium-iodide symporter; OD, optical density; qRT-PCR, quantitative real-time polymerase chain reaction; TSHR, thyroid-stimulating hormone receptor; TTF, thyroid transcription factor; TRE, tetracycline-response element; SEM, standard error of the mean. The effect of doxycycline-induced (0-1.0 mg/mL) NICD3 on Bcl-2 family protein expression was assessed by Western blotting. These proteins included the proapoptotic genes BAX, BAK, and BIM, and the antiapoptotic proteins Bcl-2 and BCL-XL. Immunoblotting was also performed for Survivin, a member of the Inhibitor-of-Apoptosis protein family. To evaluate dose-dependent alterations in the BAX/Bcl-2 ratio, Western blot band densities of BAX and Bcl-2 were calculated using ImageJ, and were normalized to b-actin band densities for each treatment group. (C) Initiation of the intrinsic apoptotic cascade following doxycycline-induced NICD3 activation was assessed by Western blotting for expression of cleaved caspases 9, 7, 3 and PARP, along with total caspases and a b-actin loading control. (D) The effect of doxycycline-induced NICD3 on the expression of cyclin family proteins, including cyclins A2, B1, and D1, was also determined by Western blotting, using b-actin as a loading control. 7-AAD, 7-aminoactinomycin D; BAK, B-cell lymphoma 2 homologous antagonist/killer; BAX, B-cell lymphoma 2-associated X protein; Bcl-2, B-cell lymphoma 2; BCL-XL, B-cell lymphoma-extra large; BIM, B-cell lymphoma 2-like protein 11; DOX, doxycycline; NICD3, Notch3 intracellular domain; PARP, poly (adenosine diphosphate-ribose) polymerase; PE, phycoerythrin; TRE, tetracycline-response element; SEM, standard error of the mean.
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Notch3 Activation Induces Transcription of Thyroid Differentiation Markers
We next measured message levels of thyrocyte-specific genes NIS, TSHR, TTF-1, and TTF-2 following NICD3 induction (Fig. 4C) . Doxycycline treatment of FTC236-NICD3 cells activated NIS and TTF-1 transcription 4.65-fold (P 5 .001) and 4.35-fold (P 5 .002), respectively, relative to no treatment. TTF-2 and TSHR transcription increased 2.1-fold (P 5 .01) and 3.1-fold (P 5 .0002), respectively. These findings suggest that Notch3 may induce transcription of genes inherent to differentiated thyrocytes.
Notch3 Induction Activates the Intrinsic Apoptotic Cascade
Using PE Annexin V/7-AAD staining, we quantified cells in apoptosis (upper right quadrant), pre-apoptosis (lower right quadrant), necrosis (upper left quadrant), and those viable in the face of doxycycline treatment (lower left quadrant; Fig. 5A ). Both 0.4 and 1.0 mg/mL of doxycycline treatment increased apoptosis to 12.5% (P 5 .006) and 37.2% (P 5 .009), respectively. Pre-apoptotic and apoptotic populations were unaffected among treated FTC236-TRE cells. We next assessed changes in intrinsic apoptotic protein expression following doxycycline treatment (0-1.0 mg/mL). Doxycycline-induced NICD3 decreased expression of the antiapoptotic protein B-cell lymphoma 2 (Bcl-2), while inducing expression of the proapoptotic B-cell lymphoma 2-associated X protein (BAX). 25 The densitometric ratio of BAX to Bcl-2, a mitochondrial permeability indicator, was significantly increased following 0.4 mg/mL of doxycycline treatment. Expression of the antiapoptotic Bcl-2 family protein Bcell lymphoma-extra large (BCL-XL) also declined with treatment, while no effect was observed on the proapoptotic Bcl-2 family proteins B-cell lymphoma 2 homologous antagonist/killer (BAK) and B-cell lymphoma 2-like protein 11 (BIM). 26 Survivin, a member of the Inhibitorof-Apoptosis family of proteins, also diminished with treatment (Fig. 5B) . NICD3 activation increased the cleavage of poly (adenosine diphosphate-ribose) polymerase (PARP) along with caspases 3, 7, and 9, and reduced the expression of all total caspases (Fig. 5C) . Collectively, caspase 9 cleavage alongside BAX induction and Bcl-2 family inhibition characterizes intrinsic apoptosis, supporting that Notch3 signaling activates this cascade. 27 Finally, NICD3 induction suppressed cell-cycle progression markers cyclin A2, cyclin B1, and cyclin D1 (Fig. 5D ). FTC236-TRE exhibited no effect. ). Failure of tumor formation was due to conditional NICD3 expression, since all other groups developed normal tumors. High-dose doxycycline chow significantly reduced FTC236-NICD3 tumor size by day 47 (P < .01) compared to doxycycline-free chow. Low-dose doxycycline treatment did retard tumor growth, but this was not significant. FTC236-TRE xenografts exhibited The mean initial tumor size of mice bearing FTC236-NICD3 tumors that were on high-dose feed was significantly smaller than that of mice with FTC236-NICD3 tumors on standard chow (P 5.008). Following visualization of palpable tumors 7 days after implantation, tumor dimensions were recorded every 3 days by external caliper measurement, and their volumes were calculated using a modified ellipsoidal formula. All analyses were performed using 2-way, repeated measures Analysis of Variance, followed by protected Fisher's least significant difference testing for post hoc comparisons (*P <.01; SAS 9.3). (B) Following the 45-day period of treatment, mice were sacrificed. Their tumors were resected, flashfrozen, and processed into whole cell lysates. Western blotting for NICD3 and a b-actin loading control were performed on representative tumor samples from each treatment group. NICD3, Notch3 intracellular domain.
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Cancer March 1, 2017 steady growth regardless of diet (Fig. 6A) . Representative tumor samples revealed NICD3 induction only among FTC236-NICD3 tumors from doxycycline-fed mice (Fig. 6B) . The degree of NICD3 expression was commensurate to the doxycycline dose, correlating negatively with tumor burden.
DISCUSSION
Thyroid cancers exist along a spectrum of differentiation and are classified accordingly. The association between thyroid cancer aggression and loss of differentiation implies that molecular triggers during development define this range of disease. Because Notch signaling during normal differentiation modulates apoptosis and cell-cycle kinetics, it has been broadly implicated in tumorigenesis. Early reports described Notch as a regulator of binary cell fate decisions in Drosophila melanogaster via inductive signaling, wherein its activation triggers differentiation and growth arrest. 28 This role is consistent in Caenorhabditis elegans and murine epithelial appendage development, which comprise gradients of differentiated cells with depressed Notch expression among early differentiated pools. 29, 30 In murine and human epidermises, Notch is expressed in later stages of keratinocyte differentiation driving mitotic exit, but is absent during the stem celldominant, proliferative phases of wound healing. 5 Recent evidence linking Notch3 to cell-cycle termination prompted our investigation into its potential tumorsuppressor role in thyroid cancer. We demonstrate that Notch3 expression declines as thyroid cancers become less differentiated and more malignant, resembling its conserved pattern in development, and thereby predicting disease prognosis. Furthermore, Notch3 activation in a gain-of-function FTC cell line inhibits cell proliferation and migration, activates the intrinsic apoptotic cascade, and reduces tumor burden in vivo.
We first demonstrate a direct relation between Notch3 and thyroid cancer differentiation. Normal thyroid lines Nthy-ori-3-1 and HTori-3 expressed higher active Notch3 than all thyroid cancer cell lines. Moreover, NOTCH3 message was diminished among lesser differentiated cell lines, but was present in FTC133, the nonmetastatic counterpart of FTC236. Consistent with this paradigm, NOTCH3 silencing in FTC133 transcriptionally suppressed thyroid-specific differentiation markers TTF-1, TTF-2, and TSHR, alongside enhancing migration, suggesting that Notch3 loss contributes to an undifferentiated, malignant phenotype. This built our rationale for using FTC236 in our gain-of-function model. Among the human samples we tested, NICD3 was present in PTC tissues, but lost across FTC and ATC. Our TMA revealed that Notch3 correlated with thyroid differentiation statuses. Mean Notch3 expression was highest among normal thyroids and lowest among ATCs. This held true both cytoplasmically and intranuclearly, which is notable since NICD3's nuclear translocation is fundamental to, and thus reflects Notch3 pathway activity.
For patients with well-differentiated thyroid cancer, the strongest predictors of disease-specific mortality include tumor size, lymph node and distant metastases, extrathyroidal extension, multifocality, being male, and being older than 45 years of age. 31 These factors are built into staging systems designed to predict clinical outcomes. We discovered that clinical features associated with poorer outcomes correlate strongly with lower Notch3 levels. Notch3 independently predicted survival when adjusted for age and colinear features including TNM stage, tumor size, extrathyroidal extension, and distant metastasis. Notch3 was not a significant predictor of survival among solely well-differentiated thyroid cancer patients, but did approach significance once adjusted for covariates. This is particularly useful because predicting mortality in this disease group, in comparison with ATC, is imprecise and multifactorial.
Although well-differentiated PTCs and FTCs are discrete diagnoses, those with high-risk profiles can devolve into lesser differentiated tumors such as ATCs, which are more lethal and clinically resistant. Therapeutic redifferentiation, therefore, aims to mitigate disease progression and improve treatment response. 3 As discussed, Notch signaling promotes differentiation in normal development and multiple cancer contexts. 5, 9, 28, 29 In thyroid cancer, we have demonstrated that Notch3 activation transcriptionally induces thyrocyte differentiation markers NIS, TSHR, TTF-1, and TTF-2, alongside reducing cell proliferation. Similarly, Ferretti et al 32 attributed transcription of thyroid-specific genes to Notch1 induction, while demonstrating its underexpression in lesser differentiated thyroid tumors. Thus, Notch3 may in part be capable of restoring a more differentiated, and hence, indolent, drug-susceptible phenotype, given its relative abundance in normal thyrocytes and differentiated tumors. In the thyroid, NIS is required for iodine uptake, while TSHR stimulates T 3 and T 4 production in response to circulating thyroid-stimulating hormone (TSH). Dedifferentiation of thyroid cancers into more aggressive tumors leads to disordered assembly of NIS and TSHR, causing refractoriness to radioiodine ablation and TSHsuppression therapy, respectively. 33, 34 Therefore, redifferentiation therapy aims to both retard tumor growth and Original Article
